Ptc Therapeutics (PTCT) Receivables - Other (2023 - 2024)
Ptc Therapeutics (PTCT) posted quarterly Receivables - Other of $800000.0 for Q1 2024, up 300.0% quarter-over-quarter from $200000.0 in Q4 2023.
Powered by 
Analysis
Ptc Therapeutics (PTCT) Receivables - Other (2023 - 2024) Analysis & Trends
Ptc Therapeutics' Receivables - Other history runs 2 years deep, the most recent figure standing at $800000.0 for Q1 2024.
- In Q1 2024, Receivables - Other changed N/A year-over-year to $800000.0; the TTM figure through Mar 2024 stood at $800000.0 (changed N/A YoY), while the FY2023 annual figure was $200000.0, changed N/A from the prior year.
- Receivables - Other for Q1 2024 stood at $800000.0, up from $200000.0 in the prior quarter.
- The five-year high for Receivables - Other was $1.4 million in Q3 2023, with the low at $200000.0 in Q4 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn |
| 10 | Ptc Therapeutics | 5.81 Bn | 3.58 Bn | 340.60 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2024 | 800,000.00 |
| Dec 31, 2023 | 200,000.00 |
| Sep 30, 2023 | 1.40 Mn |
| Jun 30, 2023 | 400,000.00 |